Sun Pharma Advanced Research Company Limited (Sparc) (NSE: SPARC, BSE: 532872) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹6,122 Cr, it ranks #769 by market cap among the 6,137 Indian listed companies on FinBizNet, and #15 of 63 in Pharmaceuticals. At ₹171.77 (as of 25 Oct 2026), the share price is 40.6% below its 52-week high of ₹289.00 and 59.0% above its 52-week low of ₹108.00. The share price is up 30.3% over one year and down 20.6% over three months.
| Current Price | ₹171.77 |
|---|---|
| Market Cap | ₹6,122 Cr |
| NSE Symbol | SPARC |
| BSE Code | 532872 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 3.9 |
| Return on Equity | 2.77% |
| Return on Assets | 79.74% |
| 52-Week Range | ₹108.00 – ₹289.00 |
| 1-Year Price Change | +30.3% |
| 3-Month Price Change | -20.6% |
| Beta (1Y) | 0.92 |
| Headquarters | Mumbai, Maharashtra |
| Website | sparc.life |
| Revenue | ₹40 Cr |
|---|---|
| Net Profit | ₹-21 Cr |
| Net Margin | -52.1% |
| EPS (Basic) | ₹-0.64 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
1. Pharmaceuticals Research and Development-This segment engages in the research and development of pharmaceutical products.
1. Pharmaceuticals Research and Development-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Sun Pharma Advanced Research Company Limited (Sparc) | ₹6,122 Cr | 3.9 | 2.77% | ₹40 Cr | +30.3% |
Listed by market capitalisation. Ratios are shown for context only.
Sun Pharma Advanced Research Company Limited (Sparc) is trading at ₹171.77, with a market capitalisation of ₹6,122 Cr.
Sun Pharma Advanced Research Company Limited (Sparc) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sun Pharma Advanced Research Company Limited (Sparc) has a P/E of 3.9 and a return on equity of 2.77%.
Sun Pharma Advanced Research Company Limited (Sparc) is listed on the NSE under the symbol SPARC and on the BSE under the scrip code 532872.
Sun Pharma Advanced Research Company Limited (Sparc)'s share price is up 30.3% over one year and down 20.6% over three months. Its 52-week range is ₹108.00 to ₹289.00.
In Q1 FY27, Sun Pharma Advanced Research Company Limited (Sparc) reported revenue of ₹40 Cr and net profit of ₹-21 Cr, with basic EPS of ₹-0.64 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.